Current advances in biomarkers for targeted therapy in triple-negative breast cancer

Brett Fleisher,1 Charlotte Clarke,2 Sihem Ait-Oudhia1 1Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, 2Department of Translational Research, UT MD Anderson Cancer Center, Houston, TX, USA Abstract: T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fleisher B, Clarke C, Ait-Oudhia S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Triple-negative breast cancer Biomarkers Targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/772a39508ac241bfa13b113d248c6af7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:772a39508ac241bfa13b113d248c6af7
record_format	dspace
spelling	oai:doaj.org-article:772a39508ac241bfa13b113d248c6af72021-12-02T08:15:41ZCurrent advances in biomarkers for targeted therapy in triple-negative breast cancer1179-1314https://doaj.org/article/772a39508ac241bfa13b113d248c6af72016-10-01T00:00:00Zhttps://www.dovepress.com/current-advances--in-biomarkers-for-targeted-therapy-in-triple-negativ-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Brett Fleisher,1 Charlotte Clarke,2 Sihem Ait-Oudhia1 1Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, 2Department of Translational Research, UT MD Anderson Cancer Center, Houston, TX, USA Abstract: Triple-negative breast cancer (TNBC) is a complex heterogeneous disease characterized by the absence of three hallmark receptors: human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor. Compared to other breast cancer subtypes, TNBC is more aggressive, has a higher prevalence in African-Americans, and more frequently affects younger patients. Currently, TNBC lacks clinically accepted targets for tailored therapy, warranting the need for candidate biomarkers. BiomarkerBase, an online platform used to find biomarkers reported in clinical trials, was utilized to screen all potential biomarkers for TNBC and select only the ones registered in completed TNBC trials through clinicaltrials.gov. The selected candidate biomarkers were classified as surrogate, prognostic, predictive, or pharmacodynamic (PD) and organized by location in the blood, on the cell surface, in the cytoplasm, or in the nucleus. Blood biomarkers include vascular endothelial growth factor/vascular endothelial growth factor receptor and interleukin-8 (IL-8); cell surface biomarkers include EGFR, insulin-like growth factor binding protein, c-Kit, c-Met, and PD-L1; cytoplasm biomarkers include PIK3CA, pAKT/S6/p4E-BP1, PTEN, ALDH1, and the PIK3CA/AKT/mTOR-related metabolites; and nucleus biomarkers include BRCA1, the glucocorticoid receptor, TP53, and Ki67. Candidate biomarkers were further organized into a “cellular protein network” that demonstrates potential connectivity. This review provides an inventory and reference point for promising biomarkers for breakthrough targeted therapies in TNBC. Keywords: anti-cancer directed pharmacotherapy, difficult-to-treat breast cancer, biological markersFleisher BClarke CAit-Oudhia SDove Medical PressarticleTriple-negative breast cancerBiomarkersTargeted therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 8, Pp 183-197 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Triple-negative breast cancer Biomarkers Targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Triple-negative breast cancer Biomarkers Targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Fleisher B Clarke C Ait-Oudhia S Current advances in biomarkers for targeted therapy in triple-negative breast cancer
description	Brett Fleisher,1 Charlotte Clarke,2 Sihem Ait-Oudhia1 1Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, 2Department of Translational Research, UT MD Anderson Cancer Center, Houston, TX, USA Abstract: Triple-negative breast cancer (TNBC) is a complex heterogeneous disease characterized by the absence of three hallmark receptors: human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor. Compared to other breast cancer subtypes, TNBC is more aggressive, has a higher prevalence in African-Americans, and more frequently affects younger patients. Currently, TNBC lacks clinically accepted targets for tailored therapy, warranting the need for candidate biomarkers. BiomarkerBase, an online platform used to find biomarkers reported in clinical trials, was utilized to screen all potential biomarkers for TNBC and select only the ones registered in completed TNBC trials through clinicaltrials.gov. The selected candidate biomarkers were classified as surrogate, prognostic, predictive, or pharmacodynamic (PD) and organized by location in the blood, on the cell surface, in the cytoplasm, or in the nucleus. Blood biomarkers include vascular endothelial growth factor/vascular endothelial growth factor receptor and interleukin-8 (IL-8); cell surface biomarkers include EGFR, insulin-like growth factor binding protein, c-Kit, c-Met, and PD-L1; cytoplasm biomarkers include PIK3CA, pAKT/S6/p4E-BP1, PTEN, ALDH1, and the PIK3CA/AKT/mTOR-related metabolites; and nucleus biomarkers include BRCA1, the glucocorticoid receptor, TP53, and Ki67. Candidate biomarkers were further organized into a “cellular protein network” that demonstrates potential connectivity. This review provides an inventory and reference point for promising biomarkers for breakthrough targeted therapies in TNBC. Keywords: anti-cancer directed pharmacotherapy, difficult-to-treat breast cancer, biological markers
format	article
author	Fleisher B Clarke C Ait-Oudhia S
author_facet	Fleisher B Clarke C Ait-Oudhia S
author_sort	Fleisher B
title	Current advances in biomarkers for targeted therapy in triple-negative breast cancer
title_short	Current advances in biomarkers for targeted therapy in triple-negative breast cancer
title_full	Current advances in biomarkers for targeted therapy in triple-negative breast cancer
title_fullStr	Current advances in biomarkers for targeted therapy in triple-negative breast cancer
title_full_unstemmed	Current advances in biomarkers for targeted therapy in triple-negative breast cancer
title_sort	current advances in biomarkers for targeted therapy in triple-negative breast cancer
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/772a39508ac241bfa13b113d248c6af7
work_keys_str_mv	AT fleisherb currentadvancesinbiomarkersfortargetedtherapyintriplenegativebreastcancer AT clarkec currentadvancesinbiomarkersfortargetedtherapyintriplenegativebreastcancer AT aitoudhias currentadvancesinbiomarkersfortargetedtherapyintriplenegativebreastcancer
_version_	1718398608151150592

Current advances in biomarkers for targeted therapy in triple-negative breast cancer

Ejemplares similares